RI-MUHC Annual Report

RI-MUHC ANNUAL REPORT 2021

YEAR IN REVIEW

CARDIOVASCULAR HEALTH ACROSS THE LIFESPAN (CHAL) PROGRAM

RESEARCH HIGHLIGHTS

Personalizing cardiovascular health

Co-led by Drs. Nadia Giannetti and Matthias Friedrich, the Courtois Cardiovascular Signature Program is a new study aiming to personalize cardiovascular health, based on each person’s unique combination of genetic, microbiotic, environmental and other factors. (cvsignature.ca)

New tools to identify patients with familial hypercholesterolemia

Dr. Jacques Genest leads the Canadian Familial Hypercholesterolemia Registry, contributing to new Canadian guidelines for diagnosis and treatment of familial hypercholesterolemia and development of the first Clinical Laboratory Improvement Amendments-certified genetic diagnostic test in Canada. These advances will improve the identification and care of patients with this disorder and reduce cardiovascular disease in this high-risk population. (FH Canada)

Assessing the effect of gender on clinical outcomes

Dr. Louise Pilote leads a data science and personalized medicine project, the Gender Outcomes INternational Group: to Further Well-being Development (GOING-FWD). This transatlantic network has developed and applied an innovative and timely framework for assessing the effect of gender on clinical outcomes. (GOING-FWD)

Drs. Nadia Giannetti, Matthias Friedrich, Jacques Genest and Louise Pilote
Drs. Nadia Giannetti, Matthias Friedrich, Jacques Genest and Louise Pilote

Selected CHAL Program news links


SELECTED PUBLICATIONS

Chantale Chantale Dumoulin, Mélanie Morin, Coraline Danieli, Lícia Pazzoto Cacciari, Marie Hélène Mayrand, Michel Tousignant, Michal Abrahamowicz. Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial. JAMA Internal Medicine 180(10): 1284-1293, 2020. doi: 10.1001/jamainternmed.2020.2993.

James M. Brophy. Bayesian Interpretation of the EXCEL Trial and Other Randomized Clinical Trials of Left Main Coronary Artery Revascularization. JAMA Internal Medicine 180(7): 986-992, 2020. doi: 10.1001/jamainternmed.2020.1647.

Anouar Hafiane, Stella S. Daskalopoulou. Adiponectin's mechanisms in high-density lipoprotein biogenesis and cholesterol efflux. Metabolism: Clinical and Experimental 113:154393, 2020. doi: 10.1016/j.metabol.2020.154393.

Ahmed AlTurki, Jacqueline Joza, Martin Louis Bernier, Riccardo Proietti, Vidal Essebag. Catheter Ablation of Atrial Fibrillation: Current and Evolving Indications. Canadian Journal of Cardiology 36(10): 1685-1689, 2020. doi: 10.1016/j.cjca.2020.01.012.

Alexandre M. Bélanger, Leo E. Akioyamen, Latifah Alothman, Jacques Genest. Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. Current Opinion in Lipidology 31(4): 176-181, 2020. doi: 10.1097/MOL.0000000000000686.

Rohan D'Souza, Rizwana Ashraf, Hilary E. Rowe, Jonathan Samuel Zipursky, Lauren Clarfield, Cynthia V. Maxwell, Cristian Arzola, Stephen Earl Lapinsky, Katryn Paquette, Srinivas N.Krishna Murthy, Matthew P. Cheng, Isabelle Malhamé. Pregnancy and COVID-19: pharmacologic considerations. Ultrasound in Obstetrics and Gynecology 57(2): 195-203, 2021. doi: 10.1002/uog.23116.

Thomas A. Mavrakanas, Katherine G. Garlo, David M. Charytan. Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clinical Journal of the American Society of Nephrology 15(8): 1146-1154, 2020. doi: 10.2215/CJN.11650919.

Victor Kočka, Pascal Thériault-Lauzier, Tianyuan Xiong, Jeremy Ben-Shoshan, Róbert Petr, Marek Laboš, Jean Buithieu, Negareh Mousavi, Thomas M. Pilgrim, Fabien Praz, Pavel Overtchouk, Jean Pierre Beaudry, Marco Spaziano, Jean Philippe Pelletier, Giuseppe Martucci, Sonny Dandona, Stéphane Rinfret, Stephan Windecker, Jonathon Avrom Leipsic, Nicoló Piazza. Optimal Fluoroscopic Projections of Coronary Ostia and Bifurcations Defined by Computed Tomographic Coronary Angiography. JACC: Cardiovascular Interventions 13(21): 2560-2570, 2020. doi: 10.1016/j.jcin.2020.06.042.

Malik Elharram, João Pedro Ferreira, Thao T. Huynh, Jiayi Ni, Nadia Giannetti, Subodh G. Verma, Faïez Mohamed Zannad, Abhinav Sharma. Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF DM) in patients in the ACCORD trial. Diabetes, Obesity and Metabolism 23(3): 782-790, 2021. doi: 10.1111/dom.14283.

Sonny Dhanani, Laura Hornby, Amanda van Beinum, Nathan B. Scales, Melanie Hogue, Andrew J. Baker, Stephen D. Beed, John Gordon Boyd, Jennifer A. Chandler, Michaël Chassé, Frédérick D'Aragon, Cameron Dezfulian, Christopher James Doig, František Duška, Jan O. Friedrich, Dale C. Gardiner, Teneille Emma Gofton, Daniel John Roberton Harvey, Christophe L. Herry, George Isac, Andreas H. Kramer, Demetrios James Kutsogiannis, David M. Maslove, Maureen Meade, Sangeeta Mehta, Laveena Munshi, Loretta Norton, Giuseppe Pagliarello, Tim O. Ramsay, Katerina Rusínová, Damon C. Scales, Matouš Schmidt, Andrew J.E. Seely, Jason Shahin, Marat Slessarev, Derek So, Heather Talbot, Walther Nicolaas Karel Anton van Mook, Petr Waldauf, Matthew John Weiss, Jentina T. Wind, Sam David Shemie. Resumption of cardiac activity after withdrawal of life-sustaining measures. New England Journal of Medicine 384(4): 345-352, 2021. doi: 10.1056/NEJMoa2022713.

rimuhc.ca/CHAL


NEXT READ

PREVIOUS READ

BACK TO

2021 Annual Report home page

RI-MUHC Annual Reports

RI-MUHC website